Table 1.
Demographic and clinical characteristics at start of follow-up in individuals with sarcoidosis and their matched general population comparators
| Sarcoidosis | General population | |
| Individuals | 8574 | 84 192 |
| Age, years | 49.5 (14.6) | 49.3 (14.5) |
| Female | 3824 (44.6) | 37 606 (44.7) |
| Region of residence | ||
| Stockholm | 1761 (20.5) | 17 323 (20.6) |
| Uppsala-Örebro | 1897 (22.1) | 18 620 (22.1) |
| West | 1543 (18.0) | 15 206 (18.1) |
| South | 1447 (16.9) | 14 198 (16.9) |
| Southeast | 977 (11.4) | 9565 (11.4) |
| North | 949 (11.1) | 9280 (11.0) |
| Country of birth* | ||
| Nordic | 7731 (90.2) | 73 841 (87.7) |
| Non-Nordic | 816 (9.5) | 10 015 (11.9) |
| Missing | 27 (0.3) | 336 (0.4) |
| Education, years | ||
| ≤9 | 1732 (20.2) | 16 974 (20.2) |
| 10–12 | 4202 (49.0) | 39 216 (46.6) |
| ≥13 | 2493 (29.1) | 26 842 (31.9) |
| Missing | 147 (1.7) | 1160 (1.4) |
| Married or in registered partnership | 4153 (48.4) | 40 366 (47.9) |
| Calendar period | ||
| 2003–2007 | 3540 (41.3) | 34 804 (41.3) |
| 2008–2013 | 5034 (58.7) | 49 388 (58.7) |
| Healthcare visits within 2 years before the first sarcoidosis visit, n | ||
| 0 | 1462 (17.1) | 43 268 (51.4) |
| 1–3 | 2180 (25.4) | 21 799 (25.9) |
| ≥4 | 4932 (57.5) | 19 125 (22.7) |
| History of morbidity† | ||
| Hypertension | 1586 (18.5) | 12 104 (14.4) |
| Diabetes mellitus | 586 (6.8) | 3176 (3.8) |
| Dyslipidaemia | 827 (9.6) | 6218 (7.4) |
| Ischaemic heart disease or acute myocardial infarction | 339 (4.0) | 2735 (3.2) |
| Atrial fibrillation | 199 (2.3) | 1361 (1.6) |
| Heart valve disease | 69 (0.8) | 470 (0.6) |
| Chronic obstructive pulmonary disease | 145 (1.7) | 681 (0.8) |
| Chronic kidney disease | 115 (1.3) | 297 (0.4) |
| Alcohol-related disorder | 184 (2.1) | 2134 (2.5) |
| Autoimmune disease | 629 (7.3) | 3428 (4.1) |
Data are n, n (%), or mean (SD). Category percentages may not sum up to 100 owing to rounding.
*Nordic countries include Sweden, Denmark, Norway, Finland and Iceland.
†Evaluated in the period up to 3 months before the first sarcoidosis visit in the National Patient Register or the corresponding date for matched general population comparators.